Will the Blood Clot Issue Hurt AstraZeneca's Vaccine in the Long Term?

·3-min read

AstraZeneca's (NASDAQ: AZN) coronavirus vaccine has struggled to gain traction after side effects were discovered. In this video from Motley Fool Live, recorded on April 12, Fool.com contributors Brian Orelli and Keith Speights discuss not only the prospects for the vaccine but also the overall prospects for the British pharmaceutical company, which is what investors should be focused on.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting